Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegenerative Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SYNJ1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SYNJ1 Recombinant Protein (WT & R258Q Mutant) High purity (>95%), Endotoxin controlled. Sequence Verified. Active domain preservation. |
View SYNJ1 Products |
| Gene Delivery | SYNJ1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and expression validation. |
View SYNJ1 Products |
| Benchmark Ab | Anti-SYNJ1 Recombinant Antibody High-affinity sequence-verified positive control for Western Blot and IHC. |
View SYNJ1 Products |
| Validator | SYNJ1 siRNA Set Target-specific knockdown verification in human neuronal models. |
View SYNJ1 Products |
| Related Target A | LRRK2 Synergistic pathway partner; interacts with SYNJ1 in synaptic vesicle endocytosis and Parkinson's disease pathogenesis. |
View LRRK2 Products |
| Related Target B | VPS35 Retromer complex component linked to familial Parkinson's disease, functionally coupled with SYNJ1-mediated lipid phosphatase activity. |
View VPS35 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High-throughput enzymatic screening of dual phosphatase domains (Sac1 and 5-phosphatase) | Recombinant proteins feature strictly verified native fold and sequence integrity, ensuring accurate theoretical MW. |
| Distinguishing wild-type activity from PARK20-associated R258Q mutant | Isogenic mutant protein panels available with >95% purity verified by SDS-PAGE. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live SYNJ1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SYNJ1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to small molecule modulators and gene therapies. As first-generation therapies reach the clinic, the next wave of R&D is targeting the specific modulation of phosphoinositide metabolism in neurodegenerative diseases like Parkinson's (PARK20) and Alzheimer's disease.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Consortia, Biotech Startups | Alzheimer's Disease, Down Syndrome | Enzymatic Assay (Need high-purity active recombinant WT protein) |
| Gene Therapy / AAV | Neurology-focused Biopharma | Parkinson's Disease (PARK20) | Expression Validation (Need Lentivirus for Stable Cell Lines) |
| RNA Therapeutics (siRNA) | RNAi Specialists | Synaptic Dysfunction, Epilepsy | Knockdown Verification (Need validated siRNA Sets) |